treats Leukemia, Non-small cell lung cancer, Nasopharyngeal carcinoma, Esophageal cancer, Liver cancer, Colorectal cancer, Breast cancer, Gastric cancer, and Lung cancer
This information is based on a systematic review of scientific literature, and was peer- reviewed and edited by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com): Dawn Costa, BA, BS (Natural Standard Research Collaboration); Nicole Giese, MS (Natural Standard Research Collaboration); Dana A. Hackman, BS (Northeastern University); Isabell Syelsky, PharmD (Northeastern University); Shaina Tanguay- Colucci, BS (Natural Standard Research Collaboration); Catherine Ulbricht, PharmD (Massachusetts General Hospital); Wendy Weissner, BA (Natural Standard Research Collaboration); Shannon Welch, PharmD (Northeastern University); Denise Wong, PharmD (Northeastern University); Jen Woods, BS (Northeastern University).
BibliographyDISCLAIMER: Natural Standard developed the above evidence- based information based on a thorough systematic review of the available scientific articles. For comprehensive information about alternative and complementary therapies on the professional level, go to www.naturalstandard.com. Selected references are listed below.
Chung CH, Go P, Chang KH. PSK immunotherapy in cancer patients- - a preliminary report. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 1987;20(3):210- 216.
Fisher M, Yang LX. Anticancer effects and mechanisms of polysaccharide- K (PSK): implications of cancer immunotherapy. Anticancer Res 2002;22(3):1737- 1754.
Hattori T, Nakajima T, Nakazato H, et al. Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/ or OK- 432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy. Jpn J Surg 1990;20(2):127- 136.
Ito K, Nakazato H, Koike A, et al. Long- term effect of 5- fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7- year follow- up. Int J Colorectal Dis 2004;19(2):157- 164.
Koda K, Miyazaki M, Sarashina H, et al. A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines. Int J Oncol 2003;23(1):165- 172.
Morimoto T, Ogawa M, Orita K, et al. Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5- year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan. Eur J Cancer 1996;32A(2):235- 242.
Nicandro JP, Tsourounis C, Frassetto L, et al. In vivo effect of I'm- Yunity on hepatic cytochrome P450 3A4. J Herb Pharmacother 2007;7(1):39- 56.
Nishiwaki Y, Furuse K, Fukuoka M, et al. [A randomized controlled study of PSK combined immuno- chemotherapy for adenocarcinoma of the lung. The Advanced Lung Cancer Immuno- chemotherapy Study Group]. Gan To Kagaku Ryoho 1990;17(1):131- 136.
Ohwada S, Ogawa T, Makita F, et al. Beneficial effects of protein- bound polysaccharide K plus tegafur/ uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters. Oncol Rep 2006 Apr;15(4):861- 8.
Ohwada S, Ikeya T, Yokomori T, et al. Adjuvant immunochemotherapy with oral Tegafur/ Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer 3- 8- 2004;90(5):1003- 1010.
Sakamoto J, Nakazato H, Ichihashi H, et al. [The minimization method in a medium size clinical trial. Study of immunochemotherapy with PSK in gastric cancer]. Gan To Kagaku Ryoho 1988;15(6):1935- 1942.
Sakamoto J, Morita S, Oba K, et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta- analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 2006 Apr;55(4):404- 11.
Shibata M, Nezu T, Kanou H, et al. Immunomodulatory effects of low dose cis- Diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer. Cancer Invest 2002;20(2):166- 173.
Sugimachi K, Maehara Y, Ogawa M, et al. Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Cancer Chemother Pharmacol 1997;40(3):233- 238.
Yamada T, Rino Y, Wada N, et al. [A case of long- term survival of 5 years after operation and chemotherapy for type 4 gastric cancer with peritoneal dissemination] Gan To Kagaku Ryoho 2008 Jan;35(1):117- 9.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.